PubMed

Hydralazine target: from blood vessels to the epigenome.

Arce C, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Candelaria M, Dueñnas-Gonzalez A.

J Transl Med. 2006 Feb 28;4:10.PMID: 16507100 [PubMed]Related articlesFree article

The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.

de la Cruz-Hernández E, Pérez-Cárdenas E, Contreras-Paredes A, Cantú D, Mohar A, Lizano M, Dueñas-González A.

Virol J. 2007 Feb 26;4:18.PMID: 17324262 [PubMed - indexed for MEDLINE]Related articlesFree article

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.PMID: 17472413 [PubMed - indexed for MEDLINE]Related articles

Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.

Meng CF, Zhu XJ, Peng G, Dai DQ.

Oncol Rep. 2009 Nov;22(5):1221-7.PMID: 19787243 [PubMed - indexed for MEDLINE]Related articles

Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines.

Meng CF, Zhu XJ, Peng G, Dai DQ.

World J Gastroenterol. 2007 Dec 14;13(46):6166-71.PMID: 18069755 [PubMed - indexed for MEDLINE]Related articlesFree article

DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML.

Müller CI, Rüter B, Koeffler HP, Lübbert M.

Curr Pharm Biotechnol. 2006 Oct;7(5):315-21. Review.PMID: 17076647 [PubMed - indexed for MEDLINE]Related articles

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.

Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G, Duenas-Gonzalez A.

Cancer Cell Int. 2006 Jan 31;6:2.PMID: 16448574 [PubMed]Related articlesFree article

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.

Song Y, Zhang C.

Cancer Chemother Pharmacol. 2009 Mar;63(4):605-13. Epub 2008 Jun 3.PMID: 18521605 [PubMed - indexed for MEDLINE]Related articles

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine.

Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Chavez-Blanco A, Revilla-Vazquez A, Benitez-Bribiesca L, Duenas-González A.

J Transl Med. 2006 Aug 7;4:32.PMID: 16893460 [PubMed]Related articlesFree article

DNA methyltransferases as targets for cancer therapy.

Ghoshal K, Bai S.

Drugs Today (Barc). 2007 Jun;43(6):395-422. Review.PMID: 17612710 [PubMed - indexed for MEDLINE]Related articles

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.

Mora-García Mde L, Duenas-González A, Hernández-Montes J, De la Cruz-Hernández E, Pérez-Cárdenas E, Weiss-Steider B, Santiago-Osorio E, Ortíz-Navarrete VF, Rosales VH, Cantú D, Lizano-Soberón M, Rojo-Aguilar MP, Monroy-García A.

J Transl Med. 2006 Dec 27;4:55.PMID: 17192185 [PubMed]Related articlesFree article

DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients.

Zhou Y, Lu Q.

Autoimmun Rev. 2008 May;7(5):376-83. Epub 2008 Apr 4. Review.PMID: 18486925 [PubMed - indexed for MEDLINE]Related articles

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, González-Fierro A, Chávez-Blanco A, de la Cruz-Hernández E, Camargo MF, Trejo-Becerril C, Pérez-Cárdenas E, Pérez-Plasencia C, Taja-Chayeb L, Wegman-Ostrosky T, Revilla-Vazquez A, Dueñas-González A.

Ann Oncol. 2007 Sep;18(9):1529-38.PMID: 17761710 [PubMed - indexed for MEDLINE]Related articlesFree article

Epigenome: a new target in cancer therapy.

Giacinti L, Vici P, Lopez M.

Clin Ter. 2008 Sep-Oct;159(5):347-60. Review.PMID: 18998037 [PubMed - indexed for MEDLINE]Related articles

The role of DNA methylation in cancer development.

Luczak MW, Jagodziński PP.

Folia Histochem Cytobiol. 2006;44(3):143-54. Review.PMID: 16977793 [PubMed - indexed for MEDLINE]Related articlesFree article

[Development of antituberculous drugs: current status and future prospects]

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese. PMID: 17240921 [PubMed - indexed for MEDLINE]Related articles

Epigenetic lesions in malignant melanoma.

Schwabe M, Lübbert M.

Curr Pharm Biotechnol. 2007 Dec;8(6):382-7. Review.PMID: 18289047 [PubMed - indexed for MEDLINE]Related articles

Dual targeting of epigenetic therapy in cancer.

Hellebrekers DM, Griffioen AW, van Engeland M.

Biochim Biophys Acta. 2007 Jan;1775(1):76-91. Epub 2006 Jul 21. Review.PMID: 16930846 [PubMed - indexed for MEDLINE]Related articles

HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma.

Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H, Mori M, Sidransky D.

Mol Cancer Res. 2008 Jan;6(1):31-41.PMID: 18234960 [PubMed - indexed for MEDLINE]Related articlesFree article

Radiosensitizing potential of epigenetic anticancer drugs.

De Schutter H, Nuyts S.

Anticancer Agents Med Chem. 2009 Jan;9(1):99-108. Review.PMID: 19149485 [PubMed - indexed for MEDLINE]Related articles